Prestige Diagnostics

Prestige Diagnostics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Prestige Diagnostics is a private, commercial-stage company operating in the diagnostics sector, generating revenue through product sales, distribution, and contract manufacturing. Its core expertise lies in IVD reagents, real-time PCR kits, and point-of-care diabetes testing, supported by an ISO 13485:2016 certified manufacturing facility. A key strategic advantage is its operational base in Northern Ireland, which under the NI Protocol provides unique regulatory and trade access to both the UK and EU markets, positioning it as a bridge for global IVD manufacturers.

Diabetes

Technology Platform

Integrated IVD manufacturing and regulatory expertise for reagents, assays (including real-time PCR), and point-of-care systems, with a specialization in HbA1c testing for diabetes management.

Opportunities

The company's position in Northern Ireland provides unique, frictionless access to both UK and EU single markets, creating a major opportunity in contract manufacturing and distribution for global IVD manufacturers post-Brexit.
Additionally, the strategic shift from central lab to point-of-care diagnostics aligns with a high-growth global trend toward decentralized, rapid testing.

Risk Factors

The core strategic advantage is dependent on the politically sensitive Northern Ireland Protocol; changes could disrupt EU market access.
The company also faces intense competition from large, established diagnostics corporations and risks associated with executing its pivot into the crowded point-of-care market.

Competitive Landscape

Prestige Diagnostics operates in the highly competitive global IVD market, competing against giants like Roche, Abbott, and Siemens Healthineers. It differentiates through agility, niche expertise in HbA1c, and its unique UK/EU regulatory positioning, acting as a specialist manufacturer and bridge for market access rather than competing head-on with broad portfolios.